GSK’s B7-H3-Targeted Antibody-Drug Conjugate, GSK’227 Gets EMA PRIME Designation in RELAPSED EXTENSIVE-STAGE SMALL-CELL LUNG CANCER .
 GSK plc, a Global Biopharma Company with a purpose to unite science, technology, and talent to get ahead of disease together, announced that the European Medicines Agency has granted Priority Medicines (PRIME) Designation for GSK’227, its B7-H3-targeted antibody-drug conjugate being evaluated for the treatment of patients with relapsed extensive-stage small-cell lung cancer (ES-SCLC) . The PRIME Designation supports the development of medicines with potential to offer a major therapeutic advantage for patients. This is the second regulatory designation for GSK’227, following the US FDA’s decision to grant Breakthrough Therapy Designation in August 2024 . Hesham Abdullah, senior VP, Global Head Oncology, R&D, GSK, said : “This PRIME Designation is an important step forward as we seek to accelerate development of GSK’227 in extensive-stage small-cell lung cancer and other tumour types with limited treatments. Our investigational B7-H3-targeted ADC is a key component of our broader ADC programme.” |
Esta designación, que sigue a una designación de terapia innovadora similar de la FDA estadounidense, destaca el potencial de GSK'227 para abordar importantes necesidades médicas no satisfechas en un subtipo de cáncer con mal pronóstico y opciones de tratamiento limitadas .
La Designación respalda los esfuerzos de GSK por acelerar el desarrollo del fármaco, mejorando su posición en el mercado oncológico y ofreciendo esperanza a las partes interesadas que buscan mejores soluciones de tratamiento en esta difícil área . ...